Hims & Hers' pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight-loss GLP-1 pill through other healthcare providers after halting distribution due to U.S. regulatory pushback.
The pill, a $49 compounded oral semaglutide version of Novo Nordisk's Wegovy, was pulled last month following FDA threats and referral to the Department of Justice.
Strive has not set a reintroduction timeline and will wait for regulatory matters to settle.
Novo Nordisk sued Hims & Hers for patent infringement related to the compounded semaglutide products.
FDA announced intent to restrict GLP-1 ingredients for non-approved compounded drugs mass-marketed as alternatives to FDA-approved options like Wegovy.